旨在初步探究脑膜中动脉（MMA）栓塞联合硬通道穿刺治疗慢性硬膜下血肿（CSDH）的安全性及有效性。

收集2019年7月至2021年2月间于首都医科大学附属北京朝阳医院接受手术治疗的40例CSDH患者。其中35例接受单纯硬通道穿刺引流术治疗；5例接受MMA栓塞治疗，必要时联合硬通道穿刺。通过微导管超选进入脑膜中动脉，利用Onyx胶选择性栓塞脑膜中动脉的责任分支，对血肿较厚及中线移位的患者立即进行硬通道血肿穿刺引流术。术后对患者进行随访，观察血肿吸收、复发情况及是否出现相关并发症。

全部40例CSDH患者手术成功率100%，所有患者血肿清除良好，无手术相关并发症。35例接受单纯硬通道穿刺引流，平均随访时间（8.1 ± 3.7）周，2例（5.7%）复发。5例慢性硬膜下血肿患者共进行了7次脑膜中动脉栓塞治疗。其中原发患者4例，复发患者1例；栓塞联合引流4例，单纯栓塞1例；单侧栓塞3例，双侧栓塞2例，中位随访时间（19.0 ± 7.0）周，随访期间均未发现复发。

初步证实脑膜中动脉栓塞联合硬通道穿刺治疗慢性硬膜下血肿安全、有效，远期疗效值得期待。

To evaluate the safty and effect of the treatment of middle meningeal artery (MMA) embolization combined with hematoma drainage on chronic subdural hematoma (CSDH).

From July 2019 to Feburary 2021, forty CSDH patients received surgical treatment in Beijing Chaoyang Hospital, Capital Medical University. Thirty five of them recived hematoma drainage. Five patients recieved MMA embolization, and if necessary, extra hematoma drainage. Selective branches of MMA embolizations was performed by Onyx. After embolization, the hematoma drainage was perfomed immediately if obvious mass effect or midline shift was confirmed on computer tomography (CT) scan. Hematoma volume resorption, recurrence and complications associated with treatment was observed during follow up.

One hundred persent of the operations were successful. Hematoma volume reduced in all the patients and no recurrence and complication that related to the treatment was seen during the follow up. Thirty-five patients received hematoma drainage. The average follow up time was (8.1 ± 3.7) weeks, two recurrences (5.7%) were seen during follow up. Five CSDH patients received a total of 7 MMA embolizations. Four of the 5 patients were primary CSDH, one of the 5 patients was recurrent. A total of 3 patients underwent unilateral interventions and 2 of them underwent bilateral interventions. The median follow up time was (19.0 ± 7.0) weeks.

Method of MMA embolization combined with hematoma drainage was safe and effective in treating CSDH, and futher result to be expected.